S
Soo Kun Lim
Researcher at University of Malaya
Publications - 63
Citations - 786
Soo Kun Lim is an academic researcher from University of Malaya. The author has contributed to research in topics: Transplantation & Organ donation. The author has an hindex of 12, co-authored 63 publications receiving 452 citations. Previous affiliations of Soo Kun Lim include University of Kuala Lumpur & University Malaya Medical Centre.
Papers
More filters
Journal ArticleDOI
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND) : a randomised, double-blind, crossover trial
David Z.I. Cherney,Claire C J Dekkers,Sean J. Barbour,Daniel C. Cattran,Abdul Halim Abdul Gafor,Peter J. Greasley,Gozewijn D. Laverman,Soo Kun Lim,Gian Luca Di Tanna,Heather N. Reich,Marc G. Vervloet,Muh Geot Wong,Ron T. Gansevoort,Hiddo J.L. Heerspink,Diamond investigators +14 more
TL;DR: 6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes, but did induce an acute and reversible decline in mGFR and a reduction in bodyweight.
Journal ArticleDOI
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima,Megumi Oshima,Meg Jardine,Meg Jardine,Rajiv Agarwal,George Bakris,Christopher P. Cannon,David M. Charytan,Dick de Zeeuw,Robert Edwards,Tom Greene,Adeera Levin,Soo Kun Lim,Kenneth W. Mahaffey,Bruce Neal,Carol A. Pollock,Norman Rosenthal,David C. Wheeler,Hong Zhang,Bernard Zinman,Vlado Perkovic,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink +22 more
TL;DR: Following the initial drop in eGFR, multivariable adjusted long-term eG FR trajectories, as well as overall and kidney safety profiles, in those treated with canagliflozin were similar across eGfr decline categories, and safety outcomes were similar among subgroups of acute e GFR drop.
Journal ArticleDOI
Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.
Desmond Y H Yap,Lawrence P. McMahon,Chuanming Hao,Nan Hu,Hirokazu Okada,Yusuke Suzuki,Sung Gyun Kim,Soo Kun Lim,Kriengsak Vareesangthip,Chi‐Chih Hung,Masaomi Nangaku +10 more
TL;DR: This recommendation summarizes the consensus views of the committee regarding the use of HIF‐PHI, taking into account both available data and expert opinion in areas where evidence remains scarce.
Journal ArticleDOI
A randomized, controlled trial of everolimus‐based dual immunosuppression versus standard of care in de novo kidney transplant recipients
Steven J. Chadban,Josette Eris,John Kanellis,Helen Pilmore,Po Chang Lee,Soo Kun Lim,Chad Woodcock,Nicol P. Kurstjens,Graeme R. Russ +8 more
TL;DR: The 12 month results from SOCRATES show noninferiority in eGFR, but a significant excess of acute rejection when everolimus was commenced at week 2 to enable a progressive withdrawal of mycophenolate and cyclosporin in kidney transplant recipients.
Journal ArticleDOI
Preliminary study of an exercise programme for reducing fatigue and improving sleep among long-term haemodialysis patients.
Radha Maniam,Pathmawathi Subramanian,Surindar Kaur Surat Singh,Soo Kun Lim,Karuthan Chinna,Roshaslina Rosli +5 more
TL;DR: Simple low-to-moderate-intensity exercise is effective for improving fatigue, sleep disorders and the overall quality of life among haemodialysis patients.